Phio Pharmaceuticals Corp. (PHIO) Stock Price & Analysis
Phio Pharmaceuticals Corp. (PHIO) closed at USD 0.85 on Friday, October 23, 2026, down 2.30% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.87; the Oct 23, 2026 session ranged USD 0.85–0.9 on volume of 28,713 shares. Market capitalization is $9.90M, with a 52-week range of USD 0.81–4.19 (NCM). Source: Nexqual, retrieved October 24, 2026 at 13:34 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PHIO.md
Key facts (PHIO)
- Insider open-market purchases, last ~7 months: 7 Form 4 filings, $69K; 0 by opportunistic insiders, 3 by routine insiders.
- Total return with dividends: 1Y -59.8% vs S&P 500 +13.4%; 5Y -99.5% vs S&P 500 +76.9%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PHIO)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$13.5M | -$11.5M | -$10.8M | -$7.4M | -$9.2M | -$13.5M |
| Net income | -$13.3M | -$11.5M | -$10.8M | -$7.2M | -$8.7M | -$12.9M |
| EPS (diluted) | -$111.87 | -$90.90 | -$46.76 | -$9.08 | — | — |
| Free cash flow | -$11.9M | -$12.3M | -$10.8M | -$7.1M | -$8.0M | -$12.2M |
| Cash + short-term investments | $24.1M | $11.8M | $8.5M | $5.4M | $21.0M | — |
| Total debt | $0K | — | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (PHIO)
P/B 0.8x · FCF yield -123.29% · Earnings yield -130.31%
Insider purchases (SEC Form 4, open-market, last ~7 months) (PHIO)
7 purchases, $69K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-09-28…2026-09-29 | Plott Ronald Todd | Director | 10,000 | $10K | 1.03 | Too little history (no open-market trades in 2023–2025) |
| 2026-09-24 | Bradford Patricia A | Director | 6,500 | $7K | 1.01 | Too little history (no open-market trades in 2023–2025) |
| 2026-09-22 | Bitterman Robert J | Chairman, Pres. & CEO | 2,000 | $2K | 1.03 | Routine (bought in Jun each year 2023–2025; this trade is outside those months) |
| 2026-09-15 | Bradford Patricia A | Director | 12,000 | $12K | 1.03 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-19 | Plott Ronald Todd | Director | 15,000 | $17K | 1.14 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-18 | Bitterman Robert J | Chairman, Pres. & CEO | 10,000 | $11K | 1.06 | Routine (bought in Jun each year 2023–2025; this trade is outside those months) |
| 2026-06-26 | Bitterman Robert J | Chairman, Pres. & CEO | 10,000 | $10K | 0.99 | Routine (bought in Jun each year 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (PHIO)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-26 | HC Wainwright & Co. | Reiterated | Buy | $14 |
Total return (dividends reinvested) (PHIO)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -59.8% | -99.5% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -59.9% | -65.8% |
| Volatility (annualized) | 77.8% | 108.2% |
| Max drawdown | -60.6% (Oct 2025→Oct 2026) | -99.7% (Apr 2022→Oct 2026) |
PHIO company outlook (results filed Aug 6, 2026)
- “The Company continues to focus its resources on advancing PH-762 while prudently managing general and administrative expenses and expects its existing cash and cash equivalents to fund planned operations into the second half of 2027.”
Quoted word-for-word from the SEC 8-K results press release.
PHIO analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.36 | $-0.33 | +10.8% | $0 | 2 |
| Next quarter (ends Dec 2026) | $-0.39 | $-0.35 | +10.0% | $0 | 2 |
| Current fiscal year (ends Dec 2026) | $-1.45 | $-1.38 | +5.1% | $0 | 2 |
| Next fiscal year (ends Dec 2027) | $-0.61 | $-0.86 | -29.1% | $0 | 2 |
Key Statistics (as of October 24, 2026 at 13:34 UTC)
| Price | USD 0.85 |
|---|---|
| Change | ▼ 2.30% (down) |
| Previous Close | USD 0.87 |
| Open | USD 0.85 |
| Day Range | USD 0.85 – 0.9 |
| 52-Week Range | USD 0.81 – 4.19 |
| Volume | 28,713 shares |
| Market Cap | $9.90M |
| Exchange | NCM |
Technical Analysis (PHIO)
Nexqual's technical model rates PHIO "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 13:34 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 28.22 (oversold) |
| vs SMA50 | Below (USD 1.03) |
| MACD | -0.04 (negative) |
Earnings (PHIO)
| EPS Estimate | USD -0.36 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.36 vs est -0.36 ▲ beat |
| 2026-03-31 | USD -0.34 vs est -0.24 ▼ miss |
| 2025-12-31 | USD -0.15 vs est -0.47 ▲ beat |
| 2025-09-30 | USD -0.44 vs est -0.44 ▲ beat |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
Financials & Fundamentals (PHIO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -113.71% |
| Current Ratio | 8.39 |
| Total Cash | $13.00M |
| Total Debt | $0 |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
Ownership (PHIO)
| Insider Ownership | +8.01% |
|---|---|
| Institutional Ownership | +10.21% |
| Shares Outstanding | 11.62M |
| Float | 11.26M |
| Short % of Float | +0.77% |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
From Phio Pharmaceuticals Corp.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Food and Drug Administration ("FDA") regulates pharmaceutical and biologic products under the FFDCA, the Public Health Service Act and other federal statutes and regulations.
- The FDA maintains several programs to facilitate and expedite the development and review of applications that are intended for the treatment of a serious or life-threatening disease or condition that meet certain other criteria, including Fast Track Designation, Breakthrough Designation, Priority Review, and the Accelerated Approval pathway.
- Our development efforts are based on our proprietary INTASYL small interfering RNA technology.
- We protect our proprietary information by means of United States and foreign patents, trademarks and copyrights.
Partnerships
- In July 2025, we announced that we had entered into a comprehensive drug substance development services agreement with a U.S. manufacturer.
- Our rights under the Advirna agreement will expire upon the later of: (i) the expiration of the last-to-expire of the "patent rights" (as defined therein) included in the Advirna agreement and (ii) the abandonment of the last-to-be abandoned of such patents, unless earlier terminated in accordance with the provisions of the Advirna agreement.
Legal & Regulatory Risks (Item 1A, quoted)
- We may be involved in litigation to protect our patents and intellectual property rights and our ability to protect our patents and intellectual property rights is uncertain and may subject us to potential liabilities.
- We may not be able to maintain compliance with the continued listing requirements of The Nasdaq Capital Market.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 303.53 | ▼ 1.39% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 89.27 | ▼ 1.79% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.09 | ▼ 0.35% |
| PRAX | Praxis Precision Medicines, Inc | USD 252.96 | ▼ 2.3% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 42.93 | ▼ 2.23% |
| AXSM | Axsome Therapeutics, Inc. | USD 145.04 | ▼ 7.07% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 13:34 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt